市場調查報告書

感染疾病診斷的全球市場 - 成長,趨勢,預測(2020年∼2025年)

Infectious Disease Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921848
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
感染疾病診斷的全球市場 - 成長,趨勢,預測(2020年∼2025年) Infectious Disease Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 112 Pages
簡介

感染疾病,是死因的主要原因之一。病原體變化,新型疾病發生之下,醫生為了決定治療方法,有選擇恰當的診斷技術的必要性。根據技術進步,以感染疾病診斷為中心情形迅速變化。質譜分析和下一代序列(NGS)等新技術和研究開發活動,改變快速診斷的方式。再加上終端用戶對POC檢驗的偏好高漲,計也促進產業的成長。還有各種主要企業,著重適合開發中國家的POC診斷解決方案的開發。

本報告提供全球感染疾病診斷市場調查,市場概要,各用途、產品、技術、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會及未來趨勢,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 感染疾病的盛行率的全世界的增加
    • 從集中型實驗室到分散式POC檢驗的焦點轉移
    • 感染疾病診斷相關研究
  • 市場阻礙因素
    • 不完全的退還制度
    • 醫療費的上升限制新診斷技術使用
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入企業的威脅
    • 替代產品、服務的威脅
    • 競爭程度

第5章 市場區隔

  • 各用途
    • 肝炎
    • 人免疫力缺乏病毒(HIV)
    • 沙眼衣原體(CT) & 淋病(NG)
    • 院內感染
    • 人類乳突病毒(HPV)
    • 結核(TB)
    • 流感
    • 其他
  • 各產品
    • 化驗、套件、試劑
    • 設備
    • 服務、軟體
  • 各技術
    • 聚合酵素鏈鎖反應(PCR)
    • 恆溫核酸增幅科技(INAAT)
    • 免疫診斷
    • DNA微陣列
    • 臨床微生物學
    • DNA序列、下一代序列(NGS)
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Biomerieux SA
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • Siemens AG
    • Thermo Fisher Scientific
    • Quidel Corporation
    • Luminex

第7章 市場機會及未來趨勢

目錄
Product Code: 67137

Market Overview

Infectious diseases are one of the leading causes of morbidity and mortality across the globe. Diagnostics is the primary step for disease discovery and treatment leading to the eradication of infectious diseases. Owing to ever-evolving pathogens and emerging new diseases, there is dire need to identify suitable diagnostics technique that can help physicians to decide the appropriate treatment. This can also help to control the outbreak of the disease in the population. Technological advancement has rapidly changed the landscape of infectious disease diagnostics. Scientific research and development activities in novel technologies and techniques such as mass spectrometry and next-generation sequencing (NGS) are changing the way how rapid diagnostics are being performed to detect diseases. In addition, the growing inclination of end-user towards point-of-care testing is also anticipated to drive industry growth. The point-of-care diagnostics provide rapid actionable information for patients' care at the real-time and site of an encounter with the healthcare system. Additionally, various major players are focused on research and development activities to develop point-of-care diagnostics solutions for developing countries.

Scope of the Report

As per the scope of the report infectious disease diagnostics involves identifying the presence of foreign antigen/organism using diagnostic tools such as kits and/or devices. In the report, a detailed analysis of the Infectious disease diagnostics market is provided. The market is evaluated by collating revenues generated across segments, categorized by product, technology, application, and geography.

Key Market Trends

Viral Infection diagnostics are expected to cover a large share of the market

A viral infection is one of the major public health concerns around the world. As per a report by Meryem Jefferies et al. published in the World Journal of Clinical Cases 2018, every year 1.4 million people die from viral hepatitis-related cirrhosis and liver cancer. Furthermore, according to the World Health Organization, 37.9 million people were living with HIV/AIDS worldwide in 2018. Moreover, an estimated 32 million people have died of HIV.

Thus, owing to the high prevalence of these dreadful illnesses, the demand for early diagnostic tests is expected to increase as early diagnosis may reduce the spread of the disease. Hence, this market is expected to increase in the future.

North America is expected to Hold Largest Market Share

According to Charbel el Bcheraoui et al. published in the Journal of the American Medical Association 2018, between 1980 and 2014, there were more than 4 million deaths due to infectious diseases recorded in the United States. In 2014, a total of more than 110,000 deaths (a rate of 34.10 deaths per 100*000 persons) were due to infectious diseases in the United States compared to a total of approximately 72,000 deaths (a rate of 41.95 deaths per 100*000 persons) in 1980.

As the United States is a developed economy, it has a well-structured healthcare system. This has helped the country with better access to the diagnostic tests that are available in the market. Diagnostic tests help early diagnosis of a disease that can help the spread of these infectious diseases. As a result, this can be noticed in the decreasing rate of infectious diseases over the years. However, the rate still remains high, which is expected to help the growth of this market

Competitive Landscape

The majority of the Infectious disease diagnostics are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market growth.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Prevalence of Infectious Diseases
    • 4.2.2 Shift in Focus From Centralized Laboratories to Decentralized Point-Of-Care Testing
    • 4.2.3 Research on Infectious Disease Diagnostics
  • 4.3 Market Restraints
    • 4.3.1 Inadequate Reimbursements
    • 4.3.2 Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Hepatitis
    • 5.1.2 Human Immunodeficiency Virus (HIV)
    • 5.1.3 Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
    • 5.1.4 Hospital-Acquired Infections
    • 5.1.5 Human Papillomavirus (HPV)
    • 5.1.6 Tuberculosis (TB)
    • 5.1.7 Influenza
    • 5.1.8 Other Infectious Diseases
  • 5.2 By Product
    • 5.2.1 Assays, Kits, & Reagents
    • 5.2.2 Instruments
    • 5.2.3 Services & Software
  • 5.3 By Technology
    • 5.3.1 Polymerase Chain Reaction (PCR)
    • 5.3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 5.3.3 Immunodiagnostics
    • 5.3.4 DNA Microarray
    • 5.3.5 Clinical Microbiology
    • 5.3.6 DNA Sequencing & Next-Generation Sequencing (NGS)
    • 5.3.7 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biomerieux SA
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 Bio-Rad Laboratories
    • 6.1.5 Danaher Corporation
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Siemens AG
    • 6.1.8 Thermo Fisher Scientific
    • 6.1.9 Quidel Corporation
    • 6.1.10 Luminex

7 MARKET OPPORTUNITIES AND FUTURE TRENDS